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1. Introduction 
According to the most recent American Cancer Society data, an estimated 569,490 
Americans died from cancer in 2010 (American Cancer Society [ACS], 2010). The number of 
cancer-related deaths recently surpassed those from heart disease in Americans <85 yrs old 
(Kung et al., 2008). Developing new and more efficacious anti-cancer compounds is a 
paramount health care priority. At the Developmental Therapeutics Program of the U.S. 
National Cancer Institute, potential therapeutic agents are typically tested for activity in an 
in vitro 60-tumor cell line screen and subsequently by in vivo xenograft studies in rodents 
(Figure 1). Once selected for additional testing using established criteria (drugability, 
novelty of structure and/or mechanism of action, potency, cell panel selectivity, etc.), 
additional studies (pharmaocokinetics, pharmacodynamics, range finding toxicity, 
formulation, mechanism of action analysis, IND-directed toxicology, etc.) are initiated 
followed by the progression of a selected few candidate agents into human clinical trials. 
Efficacious drugs with tolerable toxicity are ushered into early phase clinical trials. 
However, most of the promising compounds identified in the multi-layered preclinical 
screenings are not as successful in human patients. Therefore, preclinical models that better 
predict drug efficacy and toxicity in humans are needed. Differences in drug absorption, 
distribution, metabolism and elimination (ADME), immune responses and over-
interpretation of the preclinical efficacy data may contribute to clinical failures. However, a 
significant limitation is generating mouse models that histologically, genetically, and 
behaviorally recapitulate the human disease.  
Over the past twenty years, researchers have identified many of the underlying genetic 
abnormalities that cause certain cancers and have genetically engineered them into mouse 
models to explore the oncogenic nature of those genes and related pathways. The resulting 
mouse models generate tumors that may better mimic those seen in humans. It is 
anticipated that therapeutic compounds which show efficacy and low toxicity in these more 
human-like genetically engineered mouse (GEM) models will be more successful in clinical 
trials and lead to increased cancer survivorship. Hundreds of GEM models currently exist 
that are associated with some form of human tumor development (see the eMICE website). 
It is well beyond the scope of this manuscript to adequately describe each of them. We 
instead briefly review some of the ground-breaking GEM models developed in the 1980s 
and 90s, describe more recent and sophisticated models, highlight some of the advantages 
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and limitations for each, and explore the potential roles of molecular targeted therapies and 
GEM models in preclinical drug testing. For additional details on each model, we refer the 
reader to the original articles or prior in-depth reviews. While mice that develop genetically 
engineered tumors hold much promise, the relatively slow growth rate of these tumors and 
their low penetrance (regardless of genetics, some mice will not develop tumors during the 
time constraints of the experiment) makes them ill-suited to replace xenograft models as the 
primary in vivo screening tool. Instead, we envision GEM models as an additional screening 
mechanism that narrows and optimizes the field of therapeutic compounds before 
expensive and time-consuming human clinical trials are initiated.  
 
 
Fig. 1. Where GEMs Can Be Most Useful in the Preclinical Drug Development  
Simplistic overview of preclinical drug development procedure in the NCI/DTP. Novel 
agents are introduced through the 60 Cell Line Screen (reviewed in Monks et al., 1991), 
which contains 60 human cultured tumor cell lines in a 96-well plate array. If anti-
proliferative activity is observed in a number of cell lines, the agent is tested in a Hollow 
Fiber assay, which measures the anti-proliferative activity in cultured cells grown in hollow 
polyvinylidene fluoride (PVDF) fibers implanted intraperitoneally and subcutaneously in 
mice (reviewed in Decker et al., 2004). If active in Hollow Fiber assays, agents are 
administered to immunodeficient animals that possess human tumors generated from 
serially passaged human tumor cell lines (xenografts). Tolerable toxicity and activity 
measurable in xenograft models leads to simultaneous investigations into the agent’s 
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PK/PD, mechanism of action and toxicology. Based on this data, where applicable an IND 
application is generated for FDA approval to initiate clinical trials. The agents may require 
further preclinical studies or can be approved for a small scale Phase 0 trial (reviewed in 
Murgo et al., 2008), or initial Phase I human clinical trials. Assay Time is a best case scenario 
for a single agent and does not include time for optimization and validation repetitions. PD 
= pharmacodynamics, PK = pharmacokinetics, GEM = genetically engineered mouse, IND = 
Investigational New Drug 
2. Background: in vivo drug screening using the human tissue xenograft 
After a potential therapeutic agent shows some activity in cultured tumor cell growth 
assays, its activity and toxicity are explored through in vivo xenograft models. Fragments of 
human tumors or cultured human tumor cells are implanted (often subcutaneously) into 
immunodeficient rodents. Once the tumors grow to a predetermined size, the potential anti-
cancer agent is administered and the tumor response, generally assessed by tracking the 
tumor size, is measured over time. Drug doses and administration schedules are adjusted to 
optimize efficacy and to lower toxicity over several experimental cycles. This system 
generates valuable data and quickly returns a prediction on an agent’s activity, often in 
several months. Unfortunately, promising anti-cancer compounds discovered through this 
route often fail in human clinical trials, commonly due to low efficacy (Kerbel et al., 2003; 
Sharpless & DePinho, 2006). The low predictive value of these xenograft models exemplifies 
the need for better in vivo mouse models for preclinical drug testing.  
3. Birth of the transgenic “Oncomouse” 
Transgenic mouse technology has evolved from the early 1980s (reviewed in Palmiter & 
Brinster, 1986) such that researchers can now conditionally and reversibly alter single gene 
expression. Thousands of publications have since supported the hypothesis that oncogene 
expression or tumor suppressor gene ablation in normal mammalian cells is sufficient to 
drive tumor development. The first report of a heritable tumor-prone transgenic mouse 
came in June 1984 (Brinster et al., 1984). These mice used the SV40 enhancer region to help 
drive expression of a construct consisting of the mouse metallothionein-1 gene promoter 
fused to the thymidine kinase gene from the herpes simplex virus (HSV). They included the 
whole SV40 upstream region, consisting of enhancer, promoter, and two T-antigen genes 
transcribed in the opposite direction. It was thought the T-antigen genes would be inactive 
in mice. Unexpectedly, they observed that the transgenic mice consistently developed brain 
tumors, as well as sporadic tumors in other tissues. Follow-up experiments showed that 
using only the SV40 enhancer/promoter region and the large T-antigen gene was sufficient 
to drive tumorigenesis (Palmiter et al., 1985). Subsequent reports have shown that 
expressing the large T-antigen in a specific cell type can promote tumor development. For 
example, Ornitz et al., (1985) demonstrated expression of the large T-antigen in acinar cells 
generated exocrine pancreatic tumors, whereas Hanahan (1985) used the insulin promoter 
driving the large T-antigen specifically in pancreatic beta-cells to produce endocrine 
pancreatic tumors.  
Following the unexpected oncogenic ability of SV40, researchers tried to rationally design a 
tumor-generating transgenic mouse (“oncomouse”). In an effort to create a mouse model of 
a chromosomal translocation seen in some human B-cell lymphomas, Adams et al., (1985) 
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generated a transgene consisting of an immunoglobulin enhancer (E) driving expression of 
the Myc gene. These mice heritably develop pre-B cell and mature B-cell lymphomas. 
Further studies by Strasser et al., (1990) showed that Myc required increased expression of 
the anti-apoptotic factor Bcl-2 to drive tumorigenesis. Suppression of apoptosis is now 
understood to be a trademark of many cancer cells.  
3.1 MMTV induced breast cancer 
Using reciprocal matings between high tumor and low tumor mouse strains, Bittner (1936) 
reported tumor incidence in F1 females was dependent on the strain of the mother. 
Virologists demonstrated a virus (dubbed Murine Mammary Tumor Virus, MMTV) was 
responsible for inducing tumors in mammary tissue and was passed from mother to 
offspring through her milk. Subsequent studies showed some mouse strains also had 
MMTV virus in their eggs and sperm (reviewed in Heston & Parks, 1977).  
The utility of MMTV was expanded when it was shown that a short regulatory region 
(called long terminal repeat, LTR) was sufficient to confer hormone responsive and cell-
specific expression in vitro (Huang et al., 1981). Stewart (1984) used the MMTV LTR to drive 
Myc expression in his transgenic mice that developed breast adenocarcinomas in mammary 
epithelial tissue. Since then the MMTV LTR has been fused with a variety of purported 
oncogenes to develop tumors in murine mammary tissue that are similar in morphology 
and gene expression profile to certain types of human breast cancers (reviewed in Robles & 
Varticovski, 2008). For example, the MMTV-driven Polyoma Middle-T antigen (PyMT) 
model develops tumors similar to a human breast cancer with luminal type morphology 
approximately 2-3 months after birth (Guy et al. 1992). A model expressing MMTV-driven 
Wnt1 (wingless-type MMTV integration site family, member 1) generates mouse mammary 
tumors with characteristics similar to those of human basal type breast cancers (Huang et 
al., 2005). Several members of the Wnt gene family (encoding secretory glycoproteins that 
normally stimulate cell proliferation and differentiation) are expressed in the mouse 
mammary tissue during various stages of development. Wnt-1 is not normally expressed in 
the mammary tissue; however, when driven ectopically by MMTV, it develops oncogenic 
properties. Like most of the other “first generation” transgenic oncomice, many of these 
models have a low tumor penetrance and widely variable latency period, making them 
difficult to use directly in large scale preclinical drug screenings. These limitations are 
partially overcome by resecting and transplanting transgenically induced tumors into many 
syngeneic recipient animals, generating a large cohort of tumor-bearing animals for drug-
screening purposes (Maglione et al., 2004; Varticovski et al., 2007).  
3.2 Activated kras  
The KRAS2 gene encodes a G-protein that is a mammalian cellular homolog of a 
transforming gene isolated from the Kirsten RAt Sarcoma virus. This membrane-associated 
intracellular signal transducer plays a vital role in normal tissue signaling, proliferation, and 
differentiation (reviewed in Kranenburg, 2005). Several oncogenic point mutations interfere 
with the intrinsic GTPase activity of Kras, causing accumulation in a constitutively active 
GTP-bound state (Zenker et al., 2007). Expressing an activated Kras mutant transgene in 
acinar cells induces neoplasia in the fetal pancreas with large tumors developing only days 
after pancreatic differentiation (Quaife et al., 1987). Indeed, activating point mutations in the 
Kras gene have subsequently been shown to occur in 75 to 95% of spontaneous human 
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pancreatic cancers (Almoguero et al., 1988) as well as > 90% of spontaneous and chemically 
induced mouse lung tumors (Malkinson 1998). Activated Kras expression in the mouse lung 
generates multiple tumors at an early age, so much so that the mice succumb quickly due to 
respiratory failure (Johnson et al., 2001).  The varied penetrance and multi-focal primary 
tumor formation in addition to the short life span limits the use of this model in further 
studies of tumor development.   
3.3 Knockout oncomice 
The examples described thus far rely on the over expression of a nucleic acid sequence with 
purported oncogenic properties or mutations to drive tumorigenesis in mice. During the late 
1980’s the use of homologous recombination in mouse embryonic stem cells enabled 
researchers to inactivate (“knockout”) single genes. This technology created a new wave of 
transgenic oncomice beginning with the heterozygous null retinoblastoma (Rb) mouse 
(Jacks  et al., 1992). Rb inhibits the cell cycle by repressing expression of genes required for S 
phase progression (reviewed in Hanahan & Weiberg 2000). Mice lacking one Rb allele 
develop pituitary adenomas, whereas RB null offspring fail to develop beyond embryonic 
day 14 or 15, possibly due to excessive neuronal cell death.  
The importance of tumor suppressor expression became evident from this and other 
knockout mouse models. Various cellular stresses prompt p53 to modulate expression of its 
target genes, many of which regulate cell cycle arrest, apoptosis, DNA repair, or cellular 
metabolism. Decreased or null expression of p53 has been observed in numerous human 
cancers (reviewed in Harris & Hollstein 1993). Mice lacking one or both p53 alleles are born 
normal but are predisposed to developing spontaneous lymphomas and sarcomas later in 
life (Donehower et al., 1992). Lacking a major tumor suppressor pathway, these p53 null 
mice became a useful background with which to elucidate the oncogenic potential of other 
genes. The Rb/p53 double knockout mice develop highly aggressive tumors in the 
cerebellum visible as early as 7 weeks of age (Marino et al., 2000). Mammary and skin 
tumors develop frequently in female mice carrying conditional null Brca2 and p53 alleles 
(Jonkers et al., 2001), suggesting synergistic inactivation of Brca2 and p53 can mediate 
mammary tumorigenesis.  
Since these early transgenic and knockout mouse models have genetic alterations which are 
expressed in the germline and most, if not all, somatic cells, the models are more 
representative of human cancer predisposition syndromes. This is not the case for most 
human cancers, which develop spontaneously in a small number of cells in the adult. Many 
genes have distinct functions and expression patterns during embryonic development that 
are still poorly understood and different from those in the adult. In addition, these early 
transgenic models are notorious for their variable penetrance and tumor latency, making it 
nearly impossible to accumulate the number of animals with synchronous tumor 
development needed for large studies. While large scale production of transgenic mice is 
now possible with IVF and other high production methods (JAX® Speed Expansion Service; 
Charles River Laboratories Rapid Expansion Services), it does not obviate the issue of 
variable penetrance and tumor latency; it simply provides a large number of animals that 
can be held simultaneously to observe for tumor development. Early GEM models 
generated multiple primary lesions which far exceeded that observed in humans, limiting 
their predictive value and usefulness for preclinical studies. To better model most human 
cancers, genomic alterations should only occur in a small number of cells in the adult mouse 
tissue corresponding to the microenvironment in which the human cancer develops.  
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Fig. 2. Schematic Representation of the Tet-ON system; 1) Without the Tet-Activator (TA), 
the transgene consisting of the Gene-of-Interest (GOI) fused to the Tet-Responsive Element 
(TRE) will not be expressed. 2) Doxycycline can bind to the Tet-Activator protein, altering its 
protein structure such that TA can now bind to a TRE. 3)  If both the Tet-Activator and the 
TRE-GOI transgenes are present in the same cell, upon doxycycline administration and TA 
activation, the GOI will be transcriptionally active.   
4. Conditional and inducible oncogene expression 
The ability to alter gene expression in a normal adult mouse overcomes many confounding 
factors gene manipulation might have in embryonic development and may better 
recapitulate human disease. A widely used inducible system is the Cre-Lox model 
(reviewed in Le & Sauer, 2001; Brault et al., 2007), where a segment of DNA is flanked by 34 
base-pair (bp) LoxP sites (then referred to as floxed DNA). Co-expression of the Cre-
recombinase (by crossbreeding with a tissue-specific Cre mouse (Nagy & Mar, 2001), or 
infecting with a virus carrying Cre) causes the region between the LoxP sequences to be 
spliced out (including all or part of the gene of interest) of the genome of that individual 
cell. Researchers have used this method to permanently silence genes in mice. There are two 
main limitations to the Cre-LoxP technology. The first obstacle is resolving how to 
administer Cre such that expression occurs only in the cells of interest. Crossing floxed mice 
with mice constitutively expressing Cre in a specific tissue often results in their offspring 
containing the deletion from the embryonic stage. It is difficult to administer Cre in the 
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adult animal in a tissue-specific manner. The second limitation is the Cre-recombination 
event is irreversible and heritable.           
To overcome some of these limitations, researchers have developed the Tet-ON/OFF system 
(reviewed in Sprengel & Hasan, 2007). It requires co-expression of two transgenes in a given 
cell, usually accomplished by cross-breeding. Driven by a user defined promoter, the first 
transgene generates the inactive Tetracycline Activator (TA). Doxycycline (a more potent 
isoform of the antibiotic tetracycline) can bind to and activate TA, which can bind the 
Tetracycline Response Element (TRE) on the second transgene and drive expression of its 
gene of interest (see Figure 2). Researchers use this system to initiate gene expression in 
adult animals through doxycycline administration in their chow. Since the oncogene 
expression is tied directly to the presence of doxycycline in their diet, the oncogene can be 
activated or silenced simply by adjusting an animal’s diet. The main limitation to this 
procedure is the upfront time and labor needed to create mice that express the Tet-operator 
transgene and separate models expressing the tissue-specific Tet-activator transgene, then 
crossbreeding them to generate bi-transgenic offspring.    
Both of these inducible expression systems can be used in reverse as well if the transgene 
constructs are designed accordingly. The Cre-recombinase can excise a multiple STOP 
cassette (Lox-STOP-Lox, LSL) integrated upstream of a transcription start site, enabling 
transcription of a previously silenced gene (see Figure 3). The Tet-ON/OFF system allows 
gene expression to be repeatedly induced or silenced in multiple cycles simply by providing 
or removing doxycycline from the animal’s diet. However, the system was shown to be 
leaky in some early studies, resulting in incomplete expression inhibition or a low level of 
unregulated basal transcription. Adjunct technologies are continually being developed to 
obtain tighter gene expression control (reviewed in Freundlieb et al., 1999; Bockamp et al., 
2007) which make these systems more robust, accurate, and thus more reliable as preclinical 
models. The following examples highlight the utility of inducible GEM tumor models. 
4.1 Conditional cre-lox kras G12D system 
Taking advantage of the Lox-Stop-Lox conditional transgene expression system, Jackson et 
al., (2001) created a transgenic mouse model which replaces one wild type Kras allele with a 
transcriptionally silent oncogenic Kras-G12D allele. Intranasally delivered adenovirus 
containing the Cre-recombinase (adeno-Cre) splices out the LSL and enables expression of 
the activated Kras-G12D transgene in the lung. Small lesions can be seen 2 weeks post 
induction; by 12 weeks post induction, adenomas are observed, some with cytogenic 
characteristics of malignancy. By 16 weeks post induction, large adenomas and 
adenocarcinomas are present in many animals. Virus titrations in a number of animals 
demonstrate that the number of virus particle equivalents used for induction is directly 
related to the number of tumors that develop. 
Around the same time, Fisher et al., (2001) created an activated Kras Tet-ON/OFF inducible 
model. Doxycycline (DOX) administration induces expression of the murine oncogenic Kras 
G12D allele in alveolar type II pneumocytes. Hyperplasia is observed after just seven days 
of DOX administration; at eight weeks post induction, adenomas and adenocarcinomas are 
observed in the lungs. Removal of DOX from their diet causes a rapid decrease in activated 
Kras expression (within seven days) and apoptotic regression of the tumors. One month 
after DOX withdrawal, lesions and tumors were no longer present in the lungs, implying 
expression of the mutant Kras gene product was required to maintain the viability of tumor 
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cells. The requirement of continued oncogene expression (or constant inhibition of tumor 
suppressor) to maintain the induced tumors has given rise to the theory of “oncogene 
addiction” (reviewed in Weinstein, 2002).  
 
 
Fig. 3. CRE Recombination Mediates Lox-Stop-Lox Gene Activation. One popular method of 
inducing gene expression in adult mice is to use CRE recombination. 1) The transgenic 
mouse initially has the Lox-STOP-Lox sequence inserted upstream of the transcription start 
site for the gene of interest (GOI). This prevents GOI expression until acted upon by CRE. 
CRE recombinase is introduced to the appropriate cell population either by crossing with a 
second transgenic mouse expressing CRE recombinase using a tissue specific promoter, or 
by administering a virus expressing CRE recombinase in a tissue specific manner.  2) CRE 
recombinase splices out the STOP sequence between the two loxP sites from the transgenic 
DNA sequence, allowing GOI expression.  
Sos et al., (2009) recently used computational genomic analysis to identify molecular and 
genetic predictors of therapeutic response to clinically relevant compounds in various 
NSCLC cancer cell lines which are highly representative of primary tumors. One of their 
findings was that cells expressing activated Kras also had enhanced Hsp90 dependency. 
They used the LSL-KrasG12D model to verify this observation. Mice were initially imaged 
by MRI 12-20 weeks post adeno-Cre administration, then split into placebo and 17-
(Dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG a well-known Hsp90 
inhibitor) groups. Mice were imaged by MRI after 1 week of drug treatment; tumor volume 
was decreased by 50% in 17-DMAG treated mice while tumor volume increased slightly in 
placebo treated animals. Prior to this study, there were no molecular targeted treatments for 
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activated oncogenic Kras-driven lung tumors. But by combining the power of 
computational genomics and GEM models, researchers were able to rationally identify a 
possible therapeutic modality and evaluate its efficacy in vivo.  
4.2 Inducible oncogenic mutations in the EGF receptor 
The epidermal growth factor receptor (EGFr) is a transmembrane cell surface receptor which 
is mutated or alternatively expressed in a significant proportion of human gliomas and 
adenocarcinomas (especially of the head and neck, breast, colon, lung, and pancreas). EGFr 
is the human homolog of neu, a rat gene first identified in ethyl nitrosourea induced tumors 
(reviewed in Maguire & Greene, 1989), and is a member of the erythroblastic leukemia viral 
oncogene/human epidermal growth factor receptor (ERBB/HER) receptor tyrosine kinase 
family. Two of the most commonly observed EGFr mutations seen in lung adenocarcinomas 
include an in-frame deletion in exon 19 (eliminating an L-R-E-A [leucine-arginine-glutamic 
acid-alanine) amino acid motif that is conserved in all known vertebrate EGFr sequences) 
and a point mutation which results in a leucine to arginine substitution at position 858. 
These and other less common mutations in the kinase domain of EGFr are associated with 
increased therapeutic sensitivity to tyrosine kinase inhibitors such as gefitinib and erlotinib. 
Several studies demonstrated significantly extended survival and time to progression (TTP) 
in non-small-cell lung cancer (NSCLC) patients treated with gefitinib as their first line 
therapeutic (Han et al., 2005; Sequist et al., 2008; Yang et al., 2008). Erlotinib administration 
in patients who have had prior chemotherapy has an even greater survival benefit and is 
currently recommended by the FDA for second line therapy in new NSCLC patients 
(Shepherd et al., 2005). Inducible transgenic mouse models help to clarify this observation 
and provide a system to test other therapeutics that operate through the EGF receptor.  
Politi et al., (2006) generated several Tet-ON/OFF mouse systems which overexpress 
various mutant EGFr alleles upon DOX administration. Lung adenocarcinomas were 
observed after two months post transgene induction in the exon 19 deletion and L858R 
transgenic EGFr mouse models. Similar to the Tet On/OFF activated Kras system, after one 
month of DOX withdrawal the observed tumor load in the EGFr transgene inducible models 
regressed to near pre-induction histology. To test the anti-tumor efficacy of an already 
clinically approved therapeutic in this model, the tyrosine kinase inhibitor erlotinib was 
administered to groups of transgenic EGFr mice maintained on DOX. After less than a week 
of erlotinib treatment, all of the animals which received at least 12 mg/kg/d showed partial 
or complete responses by magnetic resonance imaging (MRI). Longer lengths of treatment 
correlated with greater tumor regression. Ji et al., (2006) generated similar inducible EGFr 
transgenic mice (exon 19 in-frame deletion or L858R), but also added a luciferase fusion 
gene to the construct. This allows for the monitoring of lung tumor growth and regression in 
vivo using a non-invasive luciferase imaging system. The ability to non-invasively image 
tumor load repeatedly in vivo enables the effects of anti-cancer drug administration to be 
followed long term as the authors demonstrated with cetuximab.    
4.3 GEMs possessing multiple genetic alterations 
Patients with lung adenocarcinomas containing one of the common EGFr oncogenic 
mutations (deletion in exon 19 of the kinase domain [Del.ex19] and leucine 858 to 
arginine[L858R]) are sensitive to the EGFr-tyrosine kinase inhibitor (TKI) therapies (gefitinib 
and erlotinib). However, the TKI treated tumors invariably relapse within a year by 
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developing resistance to the TKI therapy (reviewed in Morita et al., 2009), most commonly 
through one of the following mechanisms: EGFr-T790M point mutation (Kobayashi et al., 
2005; Pao et al., 2005), MET proto-oncogene amplification (Engelman et al., 2007), or 
hyperphosphorylation and activation of insulin-like growth factor-I receptor (Guix et al., 
2008). The EGFr-T790M mutation (observed in 50% of relapsed EGFr-mutant tumors) is 
thought to increase the ATP-binding affinity by an order of magnitude (Yun et al., 2008), 
thereby reducing the therapeutic ability of TKIs to out-compete ATP for receptor binding. 
MET amplification is thought to induce gefitinib resistance primarily by driving ERBB3 
(HER3)-dependent activation of the PI3K and Erk pathways, which regulate cell survival 
and mitogenesis, respectively (reviewed in Kim & Salgia, 2009).  
To overcome the acquired resistance of first generation TKIs, researchers have recently 
developed TKIs that bind EGFr irreversibly and are currently in or have completed phase II 
clinical trials (reviewed in Riely, 2008). The pan-ERBB inhibitor HKI-272 covalently binds to 
a cysteine in the EGFr kinase domain and regressed tumors at nanomolar concentrations in 
EGFR-L858R transgenic mice (Ji et al., 2006). The ability to inhibit ERBB2 (HER2) has led 
HKI-272 to be investigated primarily in breast cancer clinical trials (clinicaltrials.gov, 2011). 
However, other cancers driven by ErbB mutations may also be treated by HKI-272. 
Similarly, the irreversibly binding EGFr and HER2 inhibitor BIBW2992 is being tested in 
over 20 clinical trials of patients with advanced NSCLC, breast cancer, prostate cancer, 
malignant gliomas, and other solid tumors (clinicaltrials.gov, 2011). In addition to ERBB 
inhibitors, researchers are investigating other druggable targets related to the 
EGFr/HER2/ERK/AKT pathways. Shimamura et al., (2008) used an EGFR-L858R-T790M 
double transgenic GEM model to test the efficacy of an Hsp90 inhibitor, CL-387,785. Hsp90 
is a chaperone thought to aid in the proper folding of EGFr; CL-387,785 binds irreversibly to 
Hsp90 thereby interfering with its chaperone function.  
Cancer-related lethality in humans is often caused by the invasion of metastatic tumors in 
tissues far from the primary tumor. Yet few single transgene GEM models reliably develop 
metastatic lesions. By crossbreeding the pancreas-specific Cre-mediated activated Kras GEM 
(which alone generates only pre-malignant neoplasia) and the Ink4a/ARF conditional 
knockout models (does not induce neoplasia), Aguirre et al., (2003) generated mice that 
rapidly develop invasive, metastatic ductal pancreatic tumors which are lethal by 11 weeks. 
This tumor development is similar to the highly lethal human form of pancreatic ductal 
adenocarcinoma. Although the rapid murine mortality prevents long term studies, it may 
nevertheless be a useful model of a deadly human malignant cancer in short-term or cancer-
prevention studies. 
Similarly, Ji et al., (2007) crossed a lung-specific activated-Kras GEM with the following 
tumor suppressor knockout GEMs: Ink4a, p53, or the serine/threonine kinase 11 (Lkb1) 
knockout. Among the dual-knockout mice analyzed, the activated Kras x Lkb1 knockout 
had the most profound phenotype. These mice display a significantly increased lung tumor 
burden, rapid tumor onset, and <50% shorter survival when compared to the other double 
crosses or single knockout models examined. Regional lymph-node metastases were 
observed in 61% of the activated Kras x Lkb1 knockout mice, significantly more than the 
other models. The results from the previous few examples suggest an activating Kras 
mutation is responsible for initial neoplasia development, but a second mutated gene 
modulates the aggressiveness and metastatic behavior of the cancer. Accumulation of 
somatic mutations over time has long been a theory to explain the modulation and late onset 
of cancer in humans.  
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Winslow et al., (2011) expanded on this idea by administering a lentivirus expressing Cre 
recombinase to a double floxed GEM model. Upon CRE recombination, activated Kras 
would be expressed and p53 (flox/flox) would be silenced in certain cells of the adult lung. 
Because the lentivirus integrates randomly into the host cell’s genome, the authors were able 
to use linkage-mediated PCR (LM-PCR) to generate a unique “fingerprint” for each primary 
tumor and monitor that “fingerprint” in any subsequent metastases. Although virus was 
delivered at a set time point and many primary foci seemed to successfully undergo the 
oncogenic double recombination event, only a few primary foci were responsible for 
generating macroscopic metastases outside the lung, suggesting other genetic or micro-
environmental factors control a tumor’s metastatic potential. This is an excellent example of 
using an inducible, double GEM to model genetic alterations seen in many human lung 
cancers and explore the genetics of malignant and non-malignant tumors.   
Tp53 is not the only tumor suppressor being actively investigated using GEM models. The 
tumor suppressor phosphatase and tensin homologue (PTEN) is a lipid phosphatase which 
negatively regulates the PI3/AKT pathway, which is often upregulated in human 
malignancies. Sixty percent of primary human prostate cancers show a decrease/loss of 
PTEN expression; this gene also is deleteriously mutated in 70% of gliomas and in some 
forms of breast carcinomas and melanomas (Gray et al., 1998). To investigate the role of 
PTEN in prostate cancer, Trotman et al., (2003) created several PTEN GEM models, each 
with a different level of PTEN expression. Only the homozygous PTEN knockout show a 
significant phenotype (invasive prostate cancer develops after six months in all mice). 
However, none of the models generate metastases and the mice do not have decreased 
survival compared to wild type controls. A prostate-specific PTEN conditional knockout 
was created which also generated invasive prostate cancer; but in this case metastatic 
prostate tumors developed and were found in the lymph and lung (Wang et al., 2003). 
Concomitant inactivation of one or both Cdkn1b (encodes the tumor suppressor p27) alleles 
in a heterozygous PTEN knockout mouse accelerates spontaneous neoplasia formation 
which develop into prostate carcinoma at complete penetrance within three months from 
birth (Di Cristofano et al., 2001). When a conditional PTEN knockout mouse is crossed with 
a p53 knockout mouse the resulting offspring is a conditional double knockout GEM that 
develops aggressive, lethal prostate cancer with complete penetrance in seven months 
(Chen et al., 2005). The cancers observed in this new generation of GEM models recapitulate 
the progression and histopathologic features of some forms of prostate cancer observed in 
humans. These studies highlight the role of PTEN in tumorigenesis and the need for 
additional cooperative tumor suppressor inactivation to generate malignancies and lethal 
cancers.  
The potential for drug discovery and validation using conditional GEM models is 
demonstrated with the Brca1/p53 mouse model. The majority of human BRCA1-associated 
tumors harbor mutations in both p53 and BRCA1. Poole et al., (2006) created such a Cre-
LoxP conditional GEM model by inactivating both p53 and Brca1 specifically in the mouse 
mammary gland. The authors found that progesterone receptors are overexpressed in 
mutant mammary epithelial cells and presented a possible avenue of treatment. 
Administration of a progesterone agonist (mifepristone, RU 486) prevented mammary 
tumorigenesis in Brca1/p53-deficient mice. As the potential to genotype a patient’s tumor to 
determine their status for EGFr, MET, p53, IGF, and other important neoplasia-associated 
targets becomes practical, it will be possible to better choose the optimal combination 
therapy to impact the relevant oncogenic pathways.  
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5. The predictive potential of GEMs 
The potential predictive power of transgenic mice can be illustrated in the example of 
thiazolidinediones (TZDs). As an agonist of peroxisome proliferator-activated receptor-
gamma (PPAR), the TZD troglitazone had been an FDA-approved therapy for type-2 
diabetes. TZD anti-tumor activity in cultured and xenografted human colon cancer cells 
prompted excitement in the scientific community that initiated its use in Phase II clinical 
trials in patients with colon cancer (Sarraf et al., 1998).  However, in a study published a few 
pages after the xenograft study, troglitazone showed no anti-tumor activity in Min+/- mice; 
in fact, polyp formation increased with troglitazone administration in this model (Saez et al., 
1998). This heterozygous knockout mouse model lacks one functional copy of the APC 
tumor suppresser gene, thus predisposing them to colon cancer. In the Phase II clinical trial 
patients treated with troglitazone actually showed disease progression within months of 
therapy initiation, correlating with the results predicted from the transgenic mouse model 
(Kulke et al., 2002).  
5.1 Cautionary tale 
Although many regard mice as “little fuzzy humans” in the analysis of preclinical data, 
there are vast and often unknown differences in drug metabolism, gene expression, and 
disease progression between the murine model and humans. One example of transgenic 
mouse models failing to accurately predict human clinical outcome is the 
Farnesyltransferase (FTase) story. FTase catalyzes the post-translational farnesylation of 
proteins containing a C-terminal CAAX motif, where C is the cysteine residue to be 
farnesylated, A represents an aliphatic amino acid, and X is any amino acid. When X is 
leucine, the protein is a preferred substrate for a similar enzyme named 
geranylgeranyltransferase I (GGTase).  
Mendola & Backer, (1990) showed farnesylation of Ras proteins is critical for their 
transformation into potent oncogenes. This discovery ignited the hypothesis that interfering 
with prenylation using inhibitors of FTase (FTIs) or GGTase (GGTIs) could lead to tumor 
growth inhibition and a viable anti-cancer therapy. Although some data suggest an FTI and 
a GGTI need to be utilized simultaneously to achieve complete inhibition of Kras 
prenylation (Rowell et al., 1997), FTIs alone had been shown to inhibit growth of human 
tumor xenografts in nude mice (Sun et al., 1998). FTI monotherapy also demonstrates 
beneficial effects in transgenic mouse models:  tumor regression in H-Ras mice (Kohl et al., 
1995), tumor stasis in N-Ras mice (Mangues et al., 1998), and tumor growth inhibition in Ki-
RasB mice (Omer et al., 2000). These results and others spurred excitement for FTI 
monotherapy in clinical trials. With the exception of a few trials in breast cancer and 
leukemia patients, FTIs used as single agents have not shown good efficacy against solid 
tumors (reviewed in Zhu et al., 2003). Thus, none of the various mouse models evaluated 
were able to predict drug efficacy in humans. However, many clinical trials are currently 
underway combining FTIs with other drugs including “classical” anticancer therapies 
(chemotherapy or radiotherapy) and molecular targeted therapeutics.   
5.2 Targeted molecular therapeutics 
For decades, cancer therapy has been one or a combination of the following three 
treatments:  surgery, radiotherapy, and cytotoxic chemotherapy. However, all have their 
limitations and substantial side effects. Ideally, anti-cancer treatments would “target” cancer 
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cells and minimize adverse effects to non-cancerous cells. Tumors often contain gene 
expression profiles and mutations that make them more or less sensitive to some targeted 
therapies than others. Identifying the tumor’s gene expression profile and correlating it to 
the most successful therapies for that specific profile will keep therapeutic adverse side 
effects to a minimum and yield the best prognosis for the patient.  
The two main types of targeted molecular therapies are monoclonal antibodies, which target 
the receptor’s extracellular domain, and small molecule inhibitors, which target the 
intracellular signaling and kinase domains. Table 1 outlines some of the FDA-approved 
targeted therapeutics, their molecular targets, and the forms of cancer in which they have 
been proven to have a clinical benefit. Monoclonal antibodies (mabs) are generally 
administered no more than once weekly by intravenous injection, whereas small molecules 
(nibs) can generally be taken orally each day. Currently available targeted therapies may be 
administered as single agents, but many show greater benefits in combination with other 
agents or in addition to traditional therapies in those patient populations with tumors of 
susceptible genetic profiles. Tumors can be generated in genetically engineered mice which 
have these susceptible mutations and expression profiles, providing researchers with 
valuable preclinical drug screening opportunities.  
Herceptin (HER2) is a transmembrane receptor that is over-expressed in 20-25% of breast 
cancers and is associated with aggressive tumor behavior and poor prognosis (reviewed in 
Nanda, 2007). Two early studies have shown the anti-HER2 monoclonal antibody 
trastuzumab plus chemotherapy significantly improves overall survival in HER2+ patients 
with metastatic breast cancer (Slamon et al., 2005). Antibody binding is thought to inhibit 
HER2 signaling, which disrupts DNA repair mechanisms and induces cytotoxicity. 
Resistance to trastuzumab commonly occurs and can render this treatment useless in 
subsequent relapses. A recent advance has been to conjugate the antibody with a 
toxin/drug, thereby creating a “guided missile” that targets a specific epitope over-
expressed on cancer cells and delivers the toxic agent to those specific cells. Researchers at 
Genetech harvested mammary tumors from MMTV-HER2 transgenic mice, implanted them 
orthotopically into a large cohort of nude mice, staged the mice when mean tumor volumes 
were ~100-200 mm3, and administered their trastuzumab-DM1 (T-DM1) conjugate at 
various time points and doses (Jumbe et al., 2010). DM1, also known as maytansine and 
derived from members of several tropical plant families, is a potent cytotoxin that 
irreversibly inhibits tubulin polymerization and arrests cells in M or G2 phase (Remillard et 
al., 1975; Rao et al., 1979). Because the toxin is specifically targeted to tumor cells, the 
authors saw no adverse events in the mice, with ~50% of the tumors showing complete 
regression at doses of 15 mg/kg given once every three weeks.  PD/PK measures were 
obtained from the mice and this immunoconjugate therapy is now being evaluated in 
several clinical trials in patients with metastatic breast cancer.  
Several therapeutics have been developed that target the EGFr receptor to treat non-small 
cell lung cancer and colorectal cancer, including cetuximab, panitumumab, erlotinib, and 
gefitinib. Tumors expressing EGFr with a deletion in exon 19 or sensitizing point mutation 
(L858R) in the ATP-binding pocket respond significantly better to gefitinib than patients 
with wild type EGFr (Lynch et al., 2008). Invariably, even the tumors with increased drug 
sensitivity relapse when resistance to gefitinib develops. Additional therapeutics need to be 
generated to overcome the inevitable drug resistance.  
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Targeted Therapy Molecular Target Approved Use 
cetuximab (Erbitux®) EGFr Colorectal Cancer 
erlotinib (Tarceva®) EGFr 
Non-Small Cell Lung Cancer 
Metastatic Pancreatic Cancer 
gefitinib (Iressa®) EGFr Non-Small Cell Lung Cancer 
panitumumab (Vectibix®) EGFr Colorectal Cancer 
trastuzumab (Herceptin®) HER2 Early and Metastatic Breast Cancer 
lapatinib (Tykerb®) HER2 and EGFr Breast Cancer 
bevacizumab 
(Avastin®) 
VEGF 
Metastatic Colorectal Cancer 
Metastatic Melanoma 
Non-Small Cell Lung Cancer 
sunitinib (Sutent®) VEGFr and PDGFr Metastatic Renal Cell Carcinoma 
sorafenib 
(Nexavar®) 
Multi-Targeted 
Kinase Inhibitor 
Metastatic Renal Cell Carcinoma 
toceranib 
(Palladia®) 
Multi-Targeted 
Kinase Inhibitor 
Canine Specific Mastocytoma 
pazopanib 
(Votrient®) 
VEGFr, PDGFr, and 
cKIT 
Advanced Renal Cell Carcinoma 
imatinib 
(Gleevec®) 
cKIT, ABL, and 
PDGFr2 
Chronic Myeloid Leukemia and GIST 
dasatinib 
(Sprycel®) 
BCR/ABL and Src 
Family 
Chronic Myeloid Leukemia with resistance to prior 
therapy 
alemtuzumab 
(Campath®, MabCampath® 
or Campath-1H®) 
CD52 on Mature 
Lymphocytes 
Chronic Lymphocytic Leukemia (CLL) and 
Cutaneous T-cell Lymphoma (CTCL) 
ofatumumab (Arzerra®) CD20 on B-cells Chronic Lymphocytic Leukemia (CLL) 
rituximab 
(MabThera® and Rituxan®)
CD20 on B-cells B-cell Non-Hodgkin's Lymphoma 
nilotinib 
(Tasigna®) 
BCR/ABL kinase 
inhibitor 
Philadelphia chromosome positive chronic myeloid 
leukemia (CML) 
vandetanib (Zactima®) VEGFr, EGFr, RET Metastatic Medullary Thyroid Cancer 
EGFr: Epidermal growth factor receptor;erythroblastic leukemia viral (v-erb-b) oncogene homolog 1 
VEGFr: Vascular endothelial growth factor receptor 
PDGFr2: Platelet-derived growth factor receptor-alpha 
BCR/ABL:  c-abl oncogene 1, receptor tyrosine kinase 
cKIT: v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 
Her2: Herceptin receptor; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 
RET:  “Rearranged during transfection” proto oncogene 
 
 
 
 
 
Table 1. An overview of the currently FDA approved targeted therapy compounds. 
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Since vascularization is required for growth and health of a tumor, the angiogenesis 
associated factor VEGF became a desired target for therapy. Bevacizumab is an anti-VEGF 
antibody which has been shown to bind and inhibit VEGF, slowing angiogenesis and aiding 
in solid tumor starvation and elimination (Brekken et al.,  2000). When used as single agents 
in unsorted cancer patients, anti-angiogenic therapeutics do not show significant activity. 
However, when used in combination with other therapies (especially cytotoxic 
chemotherapy), subgroups of patients show promise (reviewed in Cabebe, 2007). 
Bevacizumab, in addition to paclitaxel and a platinum cytotoxic agent, is now part of a first 
line therapy for newly diagnosed non-small cell lung cancer. Hundreds of Phase II and 
Phase III trials using bevacizumab in combination with other therapies in many other 
cancers are currently ongoing (clinicaltrials.gov, 2011).  
5.3 GEM oncomice in cancer prevention 
GEM models are beginning to realize their potential as preclinical models of cancer 
prevention (briefly reviewed in Abate-Shen et al., 2008). In a recent example, Ohashi et al., 
(2009) used the EGFR-L858R-FLAG transgenic mouse to test the cancer preventative 
potential of gefitinib administration. Twenty-five 3-week old transgenic mice were 
administered gefitinib, with 5, 5, and 15 mice euthanized at weeks 8, 13, and 18, 
respectively. At termination the lungs tumors were counted and measured macroscopically 
and histologically. Those receiving gefitinib failed to develop adenocarcinomas, whereas the 
groups given vehicle control developed hyperplastic regions at 5 weeks and large 
adenocarcinomas by 15 weeks. One week after cessation of the 15-week gefitinib 
administration period, the transgenic mice showed signs of hyperplastic cell expansion in 
the lung (by PCNA staining), suggesting gefitinib was the lone factor preventing EGFr-
L858R tumor development in these mice. Longer term studies are needed to see if the EGFr-
L858R transgenic mice eventually develop gefitinib resistance, as is seen in human NCSLC 
patients with EGFr-L858R driven lung tumors. Similar studies with erlotinib, other tyrosine 
kinase inhibitors, and novel anti-cancer agents should be performed on this and other 
informative GEM models to further investigate the tumor-preventative aspects of these 
agents.  
5.4 Cancer vaccine 
It is conceivable that patients with a high risk (family history, environmental exposure, or 
heritable mutations) associated with a specific cancer subtype might benefit from being 
immunized at a young age. Vaccine development depends on the identification of antigens 
specific for a given cancer subtype or tumor-inducing biological agent. The heterogeneity 
and unstable genome in most cancers suggests resistant mutant cells might accumulate 
quickly and overcome the immunotherapy. However, vaccines against oncogenic strains of 
viruses have proven to be very beneficial and often lean on the preclinical use of GEM 
models to show the oncogenic potential of viral genes.  
In 1993, two studies using transgenic mice emerged clearly showing the oncogenic potential 
of the human papillomavirus (HPV) early genes E6 and E7 (Lambert et al., 1993; Arbeit et 
al., 1993). HPV DNA has also been found in and hypothesized by some to induce a subset of 
tongue and other oropharyngeal carcinomas (reviewed in Syrjänen, 2005). Transgenic mice 
expressing HPV early genes have been used to demonstrate the oncogenic potential of HPV 
in certain skin cancers [HPV 8 (Schaper et al., 2005) and HPV 20 (Michel et al., 2006)].  
Spurred by these and many studies elucidating the relationship between HPV and cervical 
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cancer, the FDA approved the HPV vaccine Gardasil (Merck) for preventing the most 
common forms of human papillomavirus (HPV)-induced cervical cancer (reviewed in 
McLemore, 2006). Feng et al., (2008) recently discovered a novel polyomavirus (similar to 
SV40) that integrated itself into the genome of 80% of the Merkel cell carcinomas they 
examined. Though a rare cancer, this is another example of a virus-associated cancer which 
could be a target for cancer-preventing vaccines and could be tested preclinically in GEM 
models.    
5.5 Legal obstacles of preclinical testing in GEM models  
In 1988 Harvard University filed the first of three exceptionally broad U.S. patents regarding 
the development and use of transgenic animals. Dupont (a sponsor of one of the Harvard 
investigators developing transgenic mice) became the exclusive licensee of transgenic 
patents and merely sublicensed the patent rights (imposing large fees and restrictions) to 
industry and academia. This arrangement severely constrained use of transgenic mice 
beyond basic discovery applications (reviewed in Sharpless & Depinho, 2006). Fortunately 
for the greater scientific community, the first of these patents expired in 2005 and the second 
expired in February 2009; the third patent covering testing methods using transgenic 
oncomice is still in force through 2016. Hundreds of oncomice have been developed 
(primarily in academia), but have yet to be thoroughly studied and used on a large scale to 
test the growing number of possible anti-cancer therapies. Once the final restriction is lifted, 
researchers in industry, academia, and government alike will undoubtedly expand their use 
of transgenic models for preclinical drug studies.  
6. Conclusion: Role GEMs can play in preclinical studies 
To process the thousands of novel natural product and synthetic purported anti-cancer 
compounds that arise each year, preclinical drug screens must be as quick and 
comprehensive as resources allow.  This can best be accomplished by in vitro screens using 
cultured cell lines that have oncogenic gene expression profiles similar to those seen in 
human patients. Compounds which show activity can then be moved to xenograft studies, 
which test toxicity and tumor regression potential. Although we have reviewed the power 
of GEM models in verifying drug efficacy and pathway mechanism analysis, GEM models 
as they exist today have fundamental flaws that preclude their use as high-throughput 
drug-screening tools.  
GEMs require several months to develop tumors, and the penetrance is often far less than 
100%. Tumors arise and grow at different rates in each individual mouse in a given study.  
Except for melanoma, breast cancer, and some prostate cancer models where palpable 
tumors develop, identifying which animals have developed tumors at any given moment 
becomes a nearly insurmountable task. Many published studies use MRI images to follow 
tumor progression. Considering imaging the thorax of one mouse in an MRI can take up to 
one hour, this method is incompatible with large, high throughput studies. Small animal in 
vivo imaging (SAIVI) using fluorescent or bioluminescent tagged agents targeting tumors is 
a promising alternative, but the technology is still in its infancy, lacks appropriate inducible 
GEM models for most forms of cancer, and often requires purchase of expensive, 
photosensitive probes and detection systems. Computed Tomography (CT) Imaging with 
clinical-size instruments cannot be used because the dose of radiation used during imaging 
may have therapeutic effects on the tumors, especially when GEM models will require 
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multiple imaging sessions over their lifetime to first identify a tumor and then to monitor 
therapeutic drug effects. However as smaller, less powerful, rodent-specific CT imagers 
become available to researchers, this may prove to be a useful method to measure tumor 
size in deep tissue. To best utilize current GEM models in preclinical drug trials, traditional 
tumor staging strategies must be revised so that each mouse is treated as a patient in a 
clinical trial. Therapeutic agents must not be administered en mass to all individuals in a 
treatment group at a given time point, but tailored to each mouse reflecting the date the 
tumor was recognized by whatever modality the researcher has developed. This can create a 
logistical nightmare, especially if large combination therapy treatment trials testing multiple 
vehicles, routes of administration, dosing schedules, and multiple dose concentrations are 
attempted. Day 0 should be marked at the time an animal’s measured tumor size or total 
“tumor burden” (if the GEM generates multiple foci simultaneously) crosses a pre-
determined threshold quantity.  
Therefore, we cannot envision GEM models replacing in vitro and xenograft models for the 
high throughput efficacy screens of novel agents. However, we do believe GEM models can 
be of great value during three steps in the preclinical process (Figure 1). First, if GEM 
tumors are harvested and fragments successfully implanted subcutaneously (SC) or 
orthotopically into syngeneic, immune competent mice, enough animals can be amassed to 
perform traditional xenograft-like screens with genetically desirable murine tumors 
(allografts). Varticovski et al., (2007) provide an example of this approach, harvesting 
MMTV-PyMT breast tumors from a few mice and passing them as fragments or cell 
suspensions into numerous host animals for subsequent drug studies. DNA microarrays 
were used to verify only slight changes in gene expression after two serial passages from the 
original tumor. Second passage tumors exhibited similar sensitivity to paclitaxel and 
cyclophosphamide compared to the original tumor material.  
Once an agent shows activity in vitro and in tumor transplants, GEM models can be used to 
explore the drug mechanism and further optimize in vivo dosing before an agent heads into 
the much more expensive and laborious clinical trials (Figure 1). These optimization studies 
need not be high throughput and may take a year or more to complete. Thus, fewer anti-
cancer agents will successfully pass through these additional preclinical evaluations than do 
currently advance to clinical trial. Currently, only ~5% of novel anti-cancer agents entering 
clinical trials achieve FDA approval (Kola & Landis, 2004); most of the cost and attrition 
occurs during Phase II and Phase III clinical trials. Therefore any extra time GEM-based 
drug screening would add to the preclinical drug development pipeline should be 
financially worthwhile to the drug sponsors and ethically beneficial for the volunteers 
participating in clinical trials if more efficacious therapies are discovered.      
GEM models may ultimately have a fourth role in preclinical drug testing if researchers can 
effectively “humanize” them for use in toxicology and pharmacology studies. The 
cytochrome P450 (CYP) family of enzymes are expressed primarily in the liver and are 
involved in the metabolism of a diverse range of therapeutic compounds, toxins, 
carcinogens, hormones, and xenobiotic agents we may encounter. The seven main CYP gene 
clusters found in humans are present and expanded in mice (57 putative human CYP genes 
versus 102 putative functional genes in mice) (Nelson et al., 2004). But studies have shown 
that many individual CYPs are differentially expressed or differentially active between the 
mouse and human (Bogaards et al., 2000). This explains why drug metabolism in the mouse 
does not always reflect and predict drug metabolism and toxicity in the human clinical 
trials. Several GEM models have been generated in which the endogenous mouse CYPs or 
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other xenobiotic-related metabolism genes are deleted and replaced with their human 
orthologues, or simply over express the human orthologue in addition to the mouse CYP 
(reviewed in Cheung & Gonzalez, 2008). Expression of one or two human genes certainly is 
not enough to declare a potential GEM model as functionally “humanized” and ready for 
high throughput toxicity and pharmacology studies. But as transgenic technology evolves 
and these mice express numerous human orthologues, they may indeed be able to better 
predict human drug activity and toxicity, and be of vital importance in preclinical 
therapeutic drug development.   
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